Paratek Pharmaceuticals, Inc. is making significant strides in the commercial-stage biopharmaceutical industry with its focus on developing and bringing to market life-saving therapies for life-threatening diseases and public health threats. The company's products, including NUZYRA, a broad-spectrum antibiotic, and SEYSARA, an oral therapy for moderate to severe acne vulgaris, have already made a major impact. Paratek Pharmaceuticals' strong foothold in the market is further supported by license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd., Allergan plc, Tufts University, and Biomedical Advanced Research and Development Authority. Additionally, the company has acquired a license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell XERAVATM products, while also engaging in crucial research to combat pulmonary anthrax. Founded in 1996, the company is headquartered in Boston, Massachusetts, poised to continue its efforts in improving public health across borders.